ReviewMolecules (Basel, Switzerland)2020
Towards Robust Delivery of Antimicrobial Peptides to Combat Bacterial Resistance.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Antimicrobial Peptides Targeting Salmonella enterica serovar Typhi: Mechanism of Action, Structural Insights, and Translational Challenges - A Review.Probiotics and antimicrobial proteins · 2026Review
- Transcriptomic and Molecular Insights into the Response of Multidrug-Resistant Helicobacter pylori to Human Neutrophil Peptide 1 (HNP-1).Probiotics and antimicrobial proteins · 2026Article
- Liposomal Encapsulation Reduces the Cytotoxic Effects of Gramicidin S in Monolayer and Spheroid Fibroblast Cultures.Antibiotics (Basel, Switzerland) · 2026Article
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Antimicrobial Peptides as Novel Ecological Approaches to Caries Prevention.Drug design, development and therapy · 2026Review
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Optimization strategies for antimicrobial peptides in dental caries prevention and management: from emerging mechanisms of action to clinical translation.Frontiers in microbiology · 2026Review
- Antimicrobial peptides in the era of resistance: integrating AI-driven design, host-microbe interactions, and nanotechnological delivery.Frontiers in microbiology · 2026Review
- Detailed Comprehensive Review on Advancement of Cubosomes and their Currently Available Applications.Current pharmaceutical biotechnology · 2026Review
- Antimicrobial Peptide-Loaded Mesoporous Silica Nanoparticles: A pH-Triggered Controlled Release against Biofilms.ACS omega · 2025Article
- The rise of ultrashort cationic β-peptides as promising antimicrobial therapeutics.RSC medicinal chemistry · 2025Review
- Antimicrobial Behavior of Surface-Treated Commercially Pure Titanium (CpTi) for Dental Implants in Artificial Saliva-In Vitro Study.Antibiotics (Basel, Switzerland) · 2025Article
- Influence of Peptide Conjugation Sites on Lunatin-Alumina Nanoparticles: Implications for Membrane Interaction and Antimicrobial Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Machine Learning-Assisted Prediction and Generation of Antimicrobial Peptides.Small science · 2025Article
- Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections.Pharmaceutics · 2025Review
- Antimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens.Annals of medicine and surgery (2012) · 2025Review
- Stigmurin encapsulated PLA-PEG ameliorates its therapeutic potential, antimicrobial and antiproliferative activities.Discover nano · 2025Article
- Advancements in Wound Dressing Materials: Highlighting Recent Progress in Hydrogels, Foams, and Antimicrobial Dressings.Gels (Basel, Switzerland) · 2025Review
- Antimicrobial Resistance and New Antimicrobial Agents, A Review of the Literature.Current medicinal chemistry · 2025Review
- Outer membrane vesicles fromFrontiers in molecular biosciences · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antimicrobial peptides (AMPs), otherwise known as host defence peptides (HDPs), are naturally occurring biomolecules expressed by a large array of species across the phylogenetic kingdoms. They have great potential to combat microbial infections by directly killing or inhibiting bacterial activity and/or by modulating the immune response of the host. Due to their multimodal properties, broad spectrum activity, and minimal resistance generation, these peptides have emerged as a promising response to the rapidly concerning problem of multidrug resistance (MDR). However, their therapeutic efficacy is limited by a number of factors, including rapid degradation, systemic toxicity, and low bioavailability. As such, many strategies have been developed to mitigate these limitations, such as peptide modification and delivery vehicle conjugation/encapsulation. Oftentimes, however, particularly in the case of the latter, this can hinder the activity of the parent AMP. Here, we review current delivery strategies used for AMP formulation, focusing on methodologies utilized for targeted infection site release of AMPs. This specificity unites the improved biocompatibility of the delivery vehicle with the unhindered activity of the free AMP, providing a promising means to effectively translate AMP therapy into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.